tofacitinib
pfizer
['tofa']
kubo et al. xanadu. japanese study of tofa or mtx discontinuation in ra treated with combo. relapse 60% vs 35%. recapture in 86%. low rf/acpa, bio-naive more likely to succeed. #acr22 abstr#1586 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC